Glucagon use by U.S. adults with type 1 and type 2 diabetes

J Diabetes Complications. 2021 May;35(5):107882. doi: 10.1016/j.jdiacomp.2021.107882. Epub 2021 Feb 6.

Abstract

The American Diabetes Association recommends that all patients at risk for hypoglycemia be prescribed glucagon. Despite this recommendation, there is evidence that prescription rates are lower than expected for patients with type 1 and type 2 diabetes. This study investigated prescription patterns for glucagon among de-identified administrative claims from OptumLabs® Data Warehouse for prescriptions between January 1, 2014 and December 31, 2014 among pharmacologically treated type 1 and 2 diabetes patients. We find that glucagon was rarely filled by patients with type 1 and type 2 diabetes, including fewer than 5% of patients with prior hypoglycemia requiring emergency healthcare utilization. Among patients with type 1 diabetes, glucagon fills were unpredictable and not targeted to highest risk patients.

Keywords: Adverse drug events; Glucagon; Hypoglycemia; Type 1 diabetes; Type 2 diabetes.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Diabetes Mellitus, Type 1* / drug therapy
  • Diabetes Mellitus, Type 1* / epidemiology
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetes Mellitus, Type 2* / epidemiology
  • Glucagon / therapeutic use*
  • Humans
  • Hypoglycemia* / prevention & control
  • Hypoglycemic Agents* / therapeutic use
  • Retrospective Studies
  • United States

Substances

  • Hypoglycemic Agents
  • Glucagon